Poor trial recruitment

This study will assess the effect of IT-101 on delaying cancer progression in patients with platinum sensitive ovarian cancer.

Key Inclusion Criteria:

• Women between the age of 18 and 78, inclusive;
• Evidence of platinum-sensitive ovarian cancer following the patient's primary treatment(>= 6 months);
• Received a 2nd line platinum-based chemotherapy regimen (4-6 cycles) without evidence of progression;
• May have measurable or unmeasurable disease;
• Eastern Cooperative Oncology Group (ECOG) 0 or 1;
• Ability to understand and the willingness to sign a written informed consent document.

Key Exclusion Criteria:

• Women who are pregnant or lactating;
• Prior treatment with a topoisomerase inhibitor;
• Patients with unacceptable organ and/or hematologic reserve at screening;
• Urine protein of > 500 mg/day or active nephropathy;
• Electrocardiogram (ECG) with evidence of clinically significant conduction abnormalities or active ischemia as determined by the investigator;
• History of pancreatitis within the last 12 months;
• Patients treated with previous high dose chemotherapy or stem cell transplant within the last 5 years;
• Use of any investigational agents within 4 weeks of study enrollment;
• Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, psychiatric illness or other co-morbidity that presents a risk to the patient as determined by the investigator.